Comparison of Effects of Different Heparins on Thrombin Activatable Fibrinolysis Inhibitor in Hemodialyzed Patients
暂无分享,去创建一个
[1] J. Małyszko,et al. Thrombin-activatable fibrinolysis inhibitor in kidney transplant recipient with dyslipidemia. , 2003, Transplantation proceedings.
[2] M. Myśliwiec,et al. Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[3] M. Boffa,et al. Acute Phase Mediators Modulate Thrombin-activable Fibrinolysis Inhibitor (TAFI) Gene Expression in HepG2 Cells* , 2003, The Journal of Biological Chemistry.
[4] T. Lisman,et al. Rebuttal to: Effect of heparin on TAFI‐dependent inhibition of fibrinolysis , 2003, Journal of thrombosis and haemostasis : JTH.
[5] W. März,et al. Influence of low molecular weight heparin compared to conventional heparin for anticoagulation during haemodialysis on low density lipoprotein subclasses. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[6] G. La Manna,et al. Standard Heparin versus Low-Molecular-Weight Heparin , 2002, Nephron.
[7] N. Semeraro,et al. Effect of Heparin on TAFI-Dependent Inhibition of Fibrinolysis: Relative Importance of TAFIa Generated by Clot-Bound and Fluid Phase Thrombin , 2002, Thrombosis and Haemostasis.
[8] V. Kakkar,et al. Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. , 2002, Blood.
[9] J. Małyszko,et al. Patients on peritoneal dialysis but not on hemodialysis have elevated concentration and activity of thrombin-activatable fibrinolysis inhibitor. , 2001, Thrombosis research.
[10] B. Zinman,et al. Association of a single nucleotide polymorphism in CPB2 encoding the thrombin‐activable fibrinolysis inhibitor (TAFI) with blood pressure , 2001 .
[11] M. Myśliwiec,et al. A possible role of thrombin-activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[12] A. Hartmann,et al. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[13] L. Bajzar. Thrombin Activatable Fibrinolysis Inhibitor and an Antifibrinolytic Pathway , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[14] F. Rosendaal,et al. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. , 2000, Blood.
[15] J. Westhuyzen,et al. Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[16] A. Hartmann,et al. A single dose of dalteparin effectively prevents clotting during haemodialysis. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[17] E. Ohman,et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. , 1998, Chest.
[18] H. A. Ellis. EFFECT OF HEPARIN , 2006 .
[19] M. Halks-Miller,et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. , 2002, The Journal of clinical investigation.
[20] A. Palazzuoli,et al. Different mechanisms of fibrinolysis impairment among dyslipidemic subjects. , 2001, International journal of clinical pharmacology research.
[21] E. Ohman,et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. , 2001, Chest.